Glenmark Pharmaceuticals Limited
2,121.10
INR
-62.00
(-2.84%)
ISIN
INE935A01035
Return %
Stock
S&P 500
1Y
14.66
14.39
3Y
180.18
81.42
5Y
328.63
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Glenn Mario Saldanha
- Full Time Employees
- 17,782
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Glenmark House Mumbai MA India 400099
- IPO Date
- Dec 10, 1999
- Website
- glenmarkpharma.com
- Similar Companies
- Business
- Glenmark Pharmaceuticals Limited (GLENMARK.NS) is an India-based research-led global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of branded and generic formulations across multiple therapeutic areas, including dermatology, respiratory, gastroenterology, oncology, cardiovascular, and anti-infectives. The company offers innovative branded generics and specialty products such as salt forms and novel delivery systems; key brands include Telma (telmisartan for hypertension), Candid (clotrimazole for dermatology), and Foracort (budesonide/formoterol for respiratory conditions); it also provides active pharmaceutical ingredients (APIs), contract research and manufacturing services (CRAMS), and over-the-counter (OTC) products. Glenmark operates in more than 80 countries worldwide, with key markets in India, the United States, Europe (including Germany, Italy, and the UK), Latin America, Africa, and Asia-Pacific, serving physicians, hospitals, pharmacies, and institutional customers through a network of subsidiaries and joint ventures [web:previous]. Founded in 1977 and headquartered in Mumbai, India, Glenmark Pharmaceuticals maintains manufacturing facilities in India, the Czech Republic, and Argentina, and focuses on high-growth segments like respiratory and dermatology therapies while expanding its U.S. generics portfolio and novel drug delivery platforms. In recent developments, the company launched GMRx2, a first-in-class angiotensin receptor-neuropeptide Y (NPY) antagonist for uncontrolled hypertension, completing Phase 2b trials in 2024 with positive topline results showing superior blood pressure reduction; it also secured $100 million upfront from AbbVie in a 2023 licensing deal for GRC 54276, an oral obesity treatment, potentially worth up to $1 billion in milestones [web:previous]. Additionally, Glenmark resolved U.S. FDA import alerts for its Pithampur facilities in 2024, enabling resumed exports; formed a strategic R&D collaboration withFrontier Medicines in 2024 for cancer therapies targeting undruggable proteins; and divested non-core Argentina operations to Biopas in 2023 while acquiring a majority stake in India's Siddhant Chemins in 2024 to bolster API capabilities [web:previous].
Company News
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®